Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
A couple of big sells gone through
I'd expect some proper trades once the mm's have got the minnows
will notice the RNS more tomorrow...3 month high over 8p will be gone
Glad I saw that RNS
proves the Cois sound..so much due dil. This could seriously start to re-rate
Got a long way to climb...well back above 8p for a start
One of the largest in South Korea. Things happening here...no wonder the director buys earlier in Aug
Just completely oversold Jason. Like Thomas Cooke when it went to 18p a few years back on profit warning news and then back to 180 in a couple of months. People were panicking that the bank covenants would be broken but they were weren't and Bram are now making considerable in-house savings along with having a better CEO to run the ship more efficiently with new idea's. 60p was a licence to print money. Anything under 2 quid is cheap.
This sin't a share that will attract the herd thankfully. They're not interested in mature companies with 5 -10% weekly increase. I am though...onwards to 1.80 in a month
and will soon be back at 140...then 160...then 180. Not sure how much it will kick on from there...I'm thinking 220 should be about right.
I think it will be a lot quicker than that. Well undervalued and taken down to a stupid level. £180 is the bottom price target for me and I think within a month
from Bio now re trials starting if anyone missed it.. Evgen Pharma plc Clinical Trial Approval for Phase II Study in Breast Cancer 23 August 2016 Patient recruitment will begin in the UK at Manchester’s Christie NHS Foundation Trust following Research Ethics approval, which is expected during the coming weeks. Further regulatory and Research Ethics approvals are also expected shortly at various sites across Europe in this multi-centre study. The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial will investigate SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients whose cancer cells are estrogen-receptor positive (ER+). The primary objectives of the STEM trial are to evaluate safety and efficacy (via tumour imaging) in patients starting to become resistant to mainstream hormone therapy. Patients will be enrolled into one of three study arms (SFX-01 in combination with either aromatase inhibitors, tamoxifen or fulvestrant) based on their current therapy. One proposed mechanism for the generation of resistance to hormone therapy is via the proliferation of hormone-independent breast cancer stem cells. Such cells are known to proliferate during treatment with hormonal agents and it is thought they could have the effect of repopulating the tumour to render it hormone-independent. Earlier work by the Company with xenograft models suggests that SFX-01 has the effect of reducing the number of hormone-independent cancer stem cells. The STEM trial will be led by Chief Investigator Dr Sacha Howell at Manchester’s Christie NHS Foundation Trust, Europe’s largest single-site cancer centre, and include several other sites across Europe. The first patient is expected to be recruited in October 2016. Evgen Pharma’s SFX-01 is a synthetic and stabilised version of the naturally occurring plant compound sulforaphane, a known anti-cancer agent and neuro-protective. Dr Stephen Franklin, CEO of Evgen Pharma Plc, commented: “Many therapies used in cancer ultimately fail as patients develop resistance – one hypothesis is that this resistance is driven by cancer stem cells which, unlike a mature cancer cell, do not respond to current standards of care. Our excitement with SFX-01 is that it targets the cancer stem cell population and therefore has the potential to improve the efficacy and longevity of a range of drugs used in cancer therapy – both approved drugs and those in clinical development. I would also like to take this opportunity to thank Dr Sacha Howell and colleagues at the Christie NHS Foundation Trust and the Cancer Research UK Manchester Institute for their steadfast support and encouragement.”
Another valuable piece in the jigsaw and this should now start to motor above the ipo price of last year. Just looking back at a shares mag article from last year post ipo. Northern Cap were saying 60m MCAP back then before the latest approvals etc...it's taken a year to get going but now full steam ahaed The phase II trials will run for 18 months from March 2016 and Evgen has enough cash to last until the summer of 2018, by which time a deal should be signed unless the treatments do not work. The Liverpool-based company raised £7 million at 37p per share from its initial public offering on 21 October – more than the £6.3 million it had initially planned to raise. The proceeds are funding the clinical trials as well as pre-clinical studies for a multiple sclerosis treatment. Northland Capital puts the firm’s fair value at a minimum of £60 million against a current market cap of £19.7 million. Evgen was established in 2007 by chief executive Stephen Franklin, who has two decades worth of experience on the commercial side of the life sciences industry. He helped float Provexis (PXS:AIM) on AIM in 2005. Shares says: BUY "At 27p this is a buy and hold share. Drug trial success could lead to lucrative partnership agreements or a takeover offer but investors need to understand the risks."
Tom will be fun
looking forward to seeing where this goes
Orphan drug designation gives SFX-01 the potential for US market exclusivity for seven years from the date of marketing approval. And the CEO says Highly significant
This will put the cat amoungst the pigeons
I've heard its been a decent month...this will get back to 1.60 min and it wont take long
Dont think anyone will own up to reading that tripe. Hopefully got a few of its retarded readers to sell and it will resume upwards tomorrow
Just read the RNS...profit warning and bank covernants. The H1 results have just been published though and not as bad as it first seemed. Basicaly massively oversold at present. This is a well established company with good turnover and vast product range. It's just going through a hard period but are putting inmeasures to increase profitability